Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Junshi and Ascentage Partner to Test PD-1/IAP Combination

publication date: Apr 9, 2019

Shanghai Junshi Bio and Ascentage Pharma of Suzhou joined to test a combination of Junshi's approved anti-PD-1 therapy and Ascentage's clinical-stage Inhibitor of Apoptosis Proteins (IAP), APG-1387. The trial will enroll China patients with solid and hematological tumors. In pre-clinical and early clinical tests, the combination of APG-1387 and a PD-1 immunoncology therapy showed strong antitumor activity. Junshi's Tuoyi (toripalimab) is the first domestically developed PD-1 therapy approved in China. More details....

Stock Symbol: (HK: 1877)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China